SIA Polana-D
- Address
- Viestura street 5, LV-5401 Daugavpils, Latvia
SIA Polana-D - Inflammatory Bowel Disease Research
SIA Polana-D is a clinical research center specializing in gastroenterological conditions, with particular expertise in inflammatory bowel disease research. The center focuses on evaluating novel therapeutic approaches for patients with chronic intestinal inflammatory disorders, conducting rigorous safety and efficacy assessments of emerging biologic therapies.
- Moderately to severely active ulcerative colitis treatment studies
- Comparative effectiveness research of biologic immunotherapies
- Safety monitoring and disease activity assessment in inflammatory bowel disease
The center demonstrates advanced capabilities in administering and monitoring both intravenous and subcutaneous biologic agents, including investigational treatments such as lutikizumab and established therapies like adalimumab. Their research contributes to expanding treatment options for adult patients suffering from active ulcerative colitis, helping to establish evidence-based therapeutic protocols for this challenging chronic condition.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in SIA Polana-D
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Lutikizumab Versus Adalimumab for Safety and Efficacy in Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Yet Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2024-08-19 | 2024-08-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.